

Katherine V Houser

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3423597/publications.pdf>

Version: 2024-02-01

7
papers

632
citations

1307594

7
h-index

1720034

7
g-index

7
all docs

7
docs citations

7
times ranked

1247
citing authors

#	ARTICLE	IF	CITATIONS
1	Influenza Vaccines: Challenges and Solutions. <i>Cell Host and Microbe</i> , 2015, 17, 295-300.	11.0	261
2	Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials. <i>Lancet, The</i> , 2018, 391, 552-562.	13.7	235
3	Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial. <i>Nature Medicine</i> , 2022, 28, 383-391.	30.7	65
4	DNA vaccine priming for seasonal influenza vaccine in children and adolescents 6 to 17 years of age: A phase 1 randomized clinical trial. <i>PLoS ONE</i> , 2018, 13, e0206837.	2.5	24
5	Safety and immunogenicity of investigational seasonal influenza hemagglutinin DNA vaccine followed by trivalent inactivated vaccine administered intradermally or intramuscularly in healthy adults: An open-label randomized phase 1 clinical trial. <i>PLoS ONE</i> , 2019, 14, e0222178.	2.5	18
6	A single residue in influenza virus H2 hemagglutinin enhances the breadth of the B cell response elicited by H2 vaccination. <i>Nature Medicine</i> , 2022, 28, 373-382.	30.7	16
7	Safety and immunogenicity of an HIV-1 prefusion-stabilized envelope trimer (Trimer 4571) vaccine in healthy adults: A first-in-human open-label, randomized, dose-escalation, phase 1 clinical trial. <i>EClinicalMedicine</i> , 2022, 48, 101477.	7.1	13